Sickle Cell Disease and β-Thalassemia Gene Therapy Market to Reach US$ 380.42 Million by 2033 as One-Time Curative Therapies Reshape Hematology Care

Source Summary

The global sickle cell disease and beta thalassemia gene therapy market was valued at US$83.87 million in 2024 and is projected to reach US$380.42 million by 2033, expanding at a CAGR of 18.4% during 2025-2033, according to DataM Intelligence. The